INSULIN
Overview
NovoLog Mix 70/30 is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to help improve glycemic control in adults with diabetes mellitus. It is not recommended for the treatment of diabetic ketoacidosis. The medication contains a fixed ratio of 70 percent insulin aspart protamine (an intermediate-acting insulin analog) and 30 percent insulin aspart (a rapid-acting insulin analog). This fixed combination does not allow for separate adjustments to basal (background) and prandial (mealtime) doses.
NovoLog Mix 70/30 works by mimicking the body’s natural insulin to help control blood sugar levels after meals and between meals. It combines two types of insulin analogs designed to act more predictably and consistently than human insulin.
How do I take it?
Prescribing information states that NovoLog Mix 70/30 should be administered by subcutaneous (under the skin) injection, typically twice daily. Each dose is usually taken within 15 minutes before a meal, or after starting a meal for people with type 2 diabetes. The injection can be administered in the abdomen, thigh, buttocks, or upper arm, and injection sites within a region should be rotated with each dose to reduce the risk of lipodystrophy (fat tissue changes) or localized cutaneous amyloidosis (skin tissue changes). NovoLog Mix 70/30 should not be administered intravenously or used in insulin pumps. The medication should be taken exactly as prescribed by a health care provider.
Side effects
Common side effects of NovoLog Mix 70/30 include hypoglycemia (low blood glucose), injection site reactions, lipodystrophy, rash, and pruritus (itching).
Rare but serious side effects may include anaphylaxis (severe systemic allergic reactions), hypokalemia (low potassium levels), and heart failure, especially when used with thiazolidinediones (a class of diabetes medications).
For more information about this treatment, visit:
Label: Novolog Mix 70/30- Insulin Aspart Injection, Suspension — DailyMed